Company Overview

Our mission is to improve the lives of people living with diabetes, obesity and other cardiometabolic diseases.

We are applying our proven proprietary technology platform, Arestat®, to develop a portfolio of superior, proprietary products that address areas of high unmet patient need in high value markets.

Our aim is to have multiple options to drive a step-change in company value for our shareholders.

 

Latest Documents

Developing diabetes therapies for real-world patients – CEO, Dr Sarah Howell, in Drug Discovery & Development magazine

2 October 2026

Clarivate Report – Companies to Watch 2026: Watch Arecor’s CEO talk about the company’s vision and its role in shaping the future of obesity therapies

20 August 2026

HCP Live Video: Investigational Rapid-Acting U500 Insulin Maintains Efficacy Regardless of BMI

17 August 2026

Contact: ir@arecor.com